Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

Rhea-AI Summary

Alpha Cognition (NASDAQ: ACOG) has successfully launched its product ZUNVEYL(R) (benzgalantamine) in the U.S. long-term care (LTC) market on March 17, 2025. The launch has shown positive early results with strong clinician and patient feedback, successful patient outcomes, and robust ordering momentum. The company secured Medicare reimbursement post-launch, enhancing patient access in LTC settings. Additionally, ACOG obtained a new composition of matter patent for the tablet formulation of benzgalantamine in the U.S.

Financial highlights include ZUNVEYL net product revenues of $0.35M and licensing revenue of $2.6M. Management confirmed that all launch objectives remain on track and within budget, with commercial execution proceeding according to plan.

Positive

• Successful launch of ZUNVEYL in U.S. long-term care market
• Secured Medicare reimbursement, improving market access
• Obtained new composition of matter patent for tablet formulation
• Generated $0.35M in product revenue and $2.6M in licensing revenue
• Strong initial ordering momentum and positive clinical feedback

Negative

• Initial product revenue of $0.35M indicates early-stage commercialization with limited market penetration

Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition began 2025 by launching ZUNVEYL(R) (benzgalantamine) to the U.S. long-term care (LTC) market on March 17, 2025, delivering on its commercialization timeline and budget. Early clinician and patient feedback has been positive, citing successful initial patient outcomes and strong ordering momentum, with rapid product replenishment by wholesalers. The field team reported broad engagement across high-priority LTC accounts nationwide. Importantly, Medicare reimbursement was secured soon after launch, significantly improving access for patients in LTC settings. Management reiterated that all launch objectives remain on track and within budget, with commercial execution progressing as planned.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Officially launched ZUNVEYL to US market in March, 2025.

• The Company secured a new composition of matter patent in the U.S., covering the tablet formulation of benzgalantamine.

• ZUNVEYL net product revenues of $0.35M; with licensing revenue of $2.6M.

Click image above to view full announcement.

---

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252571

FAQ

What is the revenue generated by ACOG's ZUNVEYL in Q1 2025?

ZUNVEYL generated net product revenues of $0.35M, along with licensing revenue of $2.6M in Q1 2025.

When did Alpha Cognition launch ZUNVEYL in the US market?

Alpha Cognition launched ZUNVEYL in the U.S. long-term care market on March 17, 2025.

What recent patent did Alpha Cognition (ACOG) secure for ZUNVEYL?

Alpha Cognition secured a new composition of matter patent in the U.S. covering the tablet formulation of benzgalantamine.

Has ZUNVEYL received Medicare reimbursement approval?

Yes, ZUNVEYL secured Medicare reimbursement shortly after its launch, improving access for patients in long-term care settings.

How has the market responded to ZUNVEYL's launch by Alpha Cognition?

The market response has been positive, with strong clinician and patient feedback, successful initial patient outcomes, and robust ordering momentum from wholesalers.